Abstract
INTRODUCTION: The BRAF V600E mutation is one of the most relevant genetic mutations in precision oncology. This variation is commonly found in several types of tumors, including melanoma, colorectal cancer, and thyroid cancer, to name a few. Liquid biopsy has emerged as a minimally-invasive screening option for this mutation. CONTENT: This review examines the molecular biology of the BRAF V600E mutation, its role in tumor progression, and its utility in the diagnosis, prognosis and treatment of specific types of tumors. In addition, the focus is also placed on liquid biopsy-based screening options and their advantages over solid biopsy. SUMMARY: Detection of this mutation through liquid biopsy offers a less invasive alternative to conventional tissue biopsies, with potential utility in guiding treatment adjustments and monitoring therapeutic response. OUTLOOK: The use of liquid biopsy for the detection of BRAF V600E is expected to widespread in clinical practice, leading to the optimization of disease monitoring and personalized treatments for cancer patients.